Skip to contentW
Windtree Therapeutics Inc
W
WINTWindtree Therapeutics Inc Q4 2016 · 10-K
Revenue$900.00K$900.00K+37.4% vs Q4 2015 Net Income-$6.60M-$6.60MN/M vs Q4 2015 EPS Diluted-$0.77-$0.77N/M vs Q4 2015 Operating Income-$6,368,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Windtree Therapeutics Inc · CIK 946486 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,033,000N/M Margins · derivedOperating margin-707.6%+785.7 pt vs Q4 2015
Net margin-733.6%+809.8 pt vs Q4 2015
ended Dec 31, 2016 · filed Mar 31, 2017 · 90 d after period end